

# **MYLAN LABORATORIES LIMITED** F-4 & F-12, Malegaon MIDC, Sinnar, Nashik - 422 113, Maharashtra, India.

### **CERTIFICATE OF ANALYSIS**

Name of the Product: MyHEP ALL (Sofosbuvir and Velpatasvir Film-coated Tablets 400 mg / 100 mg)				
<b>Batch No.</b> 3105979 <b>A.R. No.</b> MLNFP19010117				
Mfg. Date	Sep-2019	Market	Emerging	
Exp. Date	Aug-2021	Batch Size	2,50,000 Tablets	
Ref. Spec No.	FPSSFV195R-06	Date of Analysis	Oct 19, 2019	

S. No.	TEST	SPECIFICATION	RESULT
1	Description	Light green to green colored, modified capsule shaped biconvex beveled edge film coated tablet debossed with M on one side and SFV on the other side.	Light green colored, modified capsule shaped biconvex beveled edge film coated tablet debossed with M on one side and SFV on the other side.
2	Identification		
2.1	A. By HPLC	The retention time of the Sofosbuvir and Velpatasvir peaks in the chromatogram of the test preparation should corresponds to that in the chromatogram of the standard preparation as obtained in the test "Assay (By HPLC)".	The retention time of the Sofosbuvir and Velpatasvir peaks in the chromatogram of the test preparation corresponds to that in the chromatogram of the standard preparation as obtained in the test "Assay (By HPLC)".
2.2	B. By HPLC	Compare the spectrums of the	Compared the spectrums of the
	(With PDA detector)	Sofosbuvir and Velpatasvir peaks from the test solution chromatogram with that of the standard solution chromatogram from the PDA data. The test spectrum should match with that of standard spectrum due to Sofosbuvir and Velpatasvir peaks.	Sofosbuvir and Velpatasvir peaks from the test solution chromatogram with that of the standard solution chromatogram from the PDA data. The test spectrum matches with that of standard spectrum due to Sofosbuvir and Velpatasvir peaks
3	Dissolution (By HPLC)		
3.1	Sofosbuvir 400 mg	Complies with Ph. Eur. General Chapter 2.9.3  Not less than 80% (Q = 75%) of the labeled amount of Sofosbuvir, C 22 H 29 FN 3 O 9 P should be dissolved in 30 minutes.	(Tab-1): 94 % (Tab-2): 94 % (Tab-3): 95 % (Tab-4): 95 % (Tab-5): 93 % (Tab-6): 94 % Min: 93 % Max: 95 % Avg: 94 % RSD:0.7%
3.2	Velpatasvir 100 mg	Complies with Ph. Eur. General Chapter 2.9.3 Not less than 80% (Q = 75%) of the labeled amount of Velpatasvir, C $_{49}$ H $_{54}$ N	(Tab-1): 93 % (Tab-2): 93 % (Tab-3): 93 % (Tab-4): 94 %

Remarks: APPROVED				
- Assay results are reported as per PR#2	000039			
Prepared By : Sandip.Lachake		Approved By : Ajitl	kumar.Desai	
Prepared On : Oct 31 2019 9:28PM		Approved On: Oct 31 2019 9:35PM		
Printed by: Sandip.Lachake	Printed on: Oct 31 2019	9:41PM	Copy No.: 1	
			Page No.: 1 of 3	
Note : This document has been ger	nerated electronically and is	valid without s	ignature.	
CNo: C80000011297	•		-	
Plot No. 564/A/22, Road No. 92, Jubliee	Hills, Hyderabad - 500 034, Tela	ngana, India		
T-1 04 40 00000000 00000040 F 000	200000	-		

Tel: 91-40-30866666, 23550543, Fax: 30866699



### MYLAN LABORATORIES LIMITED F-4 & F-12, Malegaon MIDC, Sinnar, Nashik - 422 113, Maharashtra, India.

#### **CERTIFICATE OF ANALYSIS**

Name of the Product: MyHEP ALL (Sofosbuvir and Velpatasvir Film-coated Tablets 400 mg / 100 mg)				
<b>Batch No.</b> 3105979 <b>A.R. No.</b> MLNFP19010117				
Mfg. Date	Sep-2019	Market	Emerging	
Exp. Date	Aug-2021	Batch Size	2,50,000 Tablets	
Ref. Spec No.	FPSSFV195R-06	Date of Analysis	Oct 19, 2019	

S. No.	TEST	SPECIFICATION	RESULT
		<sub>8</sub> O <sub>8</sub> should	(Tab-5): 92 %
		be dissolved in 30 minutes.	(Tab-6): 94 %
			Min : 92 %
			Max : 94 %
			Avg : 93 %
			RSD:0.8%
4	Uniformity of dosage units (By		
	Content Uniformity)		
4.1	Sofosbuvir 400 mg	Complies with Ph. Eur. General	
	3	Chapter 2.9.40	Sample-1: 97.9 %
		The Acceptance Value (AV) should be	Sample-2 : 97.7 %
		not more than 15.0.	Sample-3 : 97.8 %
			Sample-4: 98.6 %
			Sample-5 : 98.9 %
			Sample-6 : 99.1 %
			Sample-7 : 98.1 %
			Sample-8: 98.4 %
			Sample-9: 99.6 %
			Sample-10 : 99.5 %
			Average : 98.6 %
			AV:1.7
4.2	Velpatasvir 100 mg	Complies with Ph. Eur. General	
	· · · <b>p</b> · · · · · · · · · · · · · · · · · · ·	Chapter 2.9.40	Sample-1: 97.9 %
		The Acceptance Value (AV) should be	Sample-2 : 98.3 %
		not more than 15.0.	Sample-3 : 98.3 %
			Sample-4: 99.0 %
			Sample-5 : 99.3 %
			Sample-6 : 99.9 %
			Sample-7: 98.6 %
			Sample-8: 98.5 %
			Sample-9: 100.3 %
			Sample-10 : 99.8 %
			Average : 99.0 %
			AV:1.9
5	Assay (By HPLC)		Av.1.9
5.1	Sofosbuvir 400 mg	Not less than 360.00 mg and not	
J. I	SOIOSBUVII 400 IIIG	more than 440.00 mg of Sofosbuvir,	In mg : 395.85 mg
		C <sub>22</sub> H <sub>29</sub> FN	In %:99.0 % w/w
		C 22   T 29   T	111 /0.33.U /0 W/W
		3 <b>∪</b> 9 <sup>Γ</sup>	

Remarks: APPROVED

Assay results are reported as per PR#2000039

Prepared By : Sandip.Lachake

Prepared On : Oct 31 2019 9:28PM

Printed by: Sandip.Lachake

Printed on: Oct 31 2019 9:41PM

Printed on: Oct 31 2019 9:41PM

Page No.: 2 of 3

Note: This document has been generated electronically and is valid without signature.

CNo: C80000011297

Plot No. 564/A/22, Road No. 92, Jubliee Hills, Hyderabad - 500 034, Telangana, India

Tel: 91-40-30866666, 23550543, Fax: 30866699



## MYLAN LABORATORIES LIMITED F-4 & F-12, Malegaon MIDC, Sinnar, Nashik - 422 113, Maharashtra, India.

#### **CERTIFICATE OF ANALYSIS**

Name of the Product: MyHEP ALL (Sofosbuvir and Velpatasvir Film-coated Tablets 400 mg / 100 mg)				
<b>Batch No.</b> 3105979 <b>A.R. No.</b> MLNFP19010117				
Mfg. Date	Sep-2019	Market	Emerging	
Exp. Date	Aug-2021	Batch Size	2,50,000 Tablets	
Ref. Spec No.	FPSSFV195R-06	Date of Analysis	Oct 19, 2019	

S. No.	TEST	SPECIFICATION	RESULT
		(90.0% w/w - 110.0% w/w of labeled	
		amount of Sofosbuvir)	
5.2	Velpatasvir 100 mg	Not less than 90.00 mg and not more	
		than 110.00 mg of Velpatasvir, C	In mg : 98.32 mg
		<sub>49</sub> H <sub>54</sub> N	In %:98.3 % w/w
		<sub>8</sub> O <sub>8</sub>	
		(90.0% w/w - 110.0% w/w of labeled	
		amount of Velpatasvir)	
6	Related Substances (By HPLC)		
6.1	A.Velpatasvir impurities:		
6.1.1	a.Amine free base	Not more than 1.0% w/w	Not Detected
6.1.2	b.Lactone impurity	Not more than 1.0% w/w	0.021 % w/w
6.1.3	c. Any unknown impurity	Not more than 0.5% w/w	0.046 % w/w
6.2	B.Sofosbuvir impurities:		
6.2.1	a.Fluoro uridine impurity	Not more than 0.5% w/w	Not Detected
6.2.2	b. Any unknown impurity	Not more than 0.5% w/w	0.045 % w/w
6.3	C.Total impurities (A + B)	Not more than 3.5% w/w	0.155 % w/w
7	Residual solvents (By GC)		
7.1	Ethanol	Not more than 5000 ppm	294 ppm
8	Water (By KF)	Not more than 5.5% w/w	3.02 % w/w

Storage: Do not store above 30 ℃, store in origina I container.

Remarks: APPROVED

Assay results are reported as per PR#2000039

Prepared By: Sandip.Lachake

Approved By: Ajitkumar.Desai

Prepared On: Oct 31 2019 9:28PM

Approved On: Oct 31 2019 9:35PM

Printed by: Sandip.Lachake

Printed by: Sandip.Lachake Printed on: Oct 31 2019 9:41PM Copy No.: 1
Page No.: 3 of 3

Note: This document has been generated electronically and is valid without signature.

CNo: C80000011297

Plot No. 564/A/22, Road No. 92, Jubliee Hills, Hyderabad - 500 034, Telangana, India

Tel: 91-40-30866666, 23550543, Fax: 30866699